Colestid

(Colestipol)

Phase 3Small molecule

Pfizer

Colestid is one of 57 small molecule programs targeting Atherosclerosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

AtherosclerosisActive, not recruiting

Cutaneous PorphyriaActive, not recruiting

Breast CancerActive, not recruiting

AtherosclerosisPhase 3

Active, not recruiting

Cutaneous PorphyriaPhase 2/Phase 3

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Colestid

Pfizer

Phase 3

1 2

Trodelvy

Gilead

Preclinical

37 3

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 4

Zolymbus

AbbVie

Preclinical

1 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 6

Chirocaine

PPurdue Pharma LP

Preclinical

1 7

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 8

Vfend

PPrism Pharmaceuticals

Preclinical

—9

Apatinib Mesylate

BBukwang Pharmaceutical

Preclinical

3 10

Dextromethorphan Hydrobromide

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Atherosclerosis2 trials

Cholesterol-Lowering Atherosclerosis Study (CLAS)

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT00000599

Familial Atherosclerosis Treatment Study

Completed·UUniversity of Washington·Phase 3·NCT00000512·146 enrolled

Breast Cancer1 trial

An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide

Completed·PPuma Biotechnology, Inc.·Phase 2·NCT02400476·563 enrolled

Prospective1 trial

A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction

Completed·TTuscaloosa Research & Education Advancement Corporation·Phase 4·NCT00203476·30 enrolled

Cutaneous Porphyria1 trial

Sorbent Therapy of the Cutaneous Porphyrias

Completed·—·Phase 2/3·NCT01422915·4 enrolled

Unspecified1 trial

Rapid Elimination Procedure of Teriflunomide With Colestipol Hydrochloride

Terminated·DDerrick Scott Robertson·Phase 1·NCT02263547·14 enrolled

Regulatory

FDA Approval Timeline[4]

Jul 19, 1994

COLESTID

NDA NDA020222

Sep 22, 1995

COLESTID

NDA NDA017563

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Colestipol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Colestipol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Colestipol. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA017563). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Pfizer

Colestid

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Atherosclerosis2 trials

Breast Cancer1 trial

Prospective1 trial

Cutaneous Porphyria1 trial

Unspecified1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News